Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2612]

ESMO 2024: Encoradenib & binimetinib shows long-term clinically meaningful response in patients with BRAF V600E-mutant metastatic non-small Cell lung cancer

ESMO 2024: Encoradenib & binimetinib shows long-term clinically meaningful response in patients with BRAF V600E...

FDA approves pembrolizumab with chemotherapy for unresectable advanced or metastatic malignant pleural mesothelioma

FDA approves pembrolizumab with chemotherapy for unresectable advanced or metastatic malignant pleural mesothelioma

FDA approves atezolizumab and hyaluronidase-tqjs for subcutaneous injection

FDA approves atezolizumab and hyaluronidase-tqjs for subcutaneous injection

New, rare type of small cell lung cancer identified by research team

New, rare type of small cell lung cancer identified by research team

WCLC 2024: Phase II study of taletrectinib shows clinically meaningful overall response and favorable safety in patients with ROS1+ non-small cell lung cancer

WCLC 2024: Phase II study of taletrectinib shows clinically meaningful overall response and favorable safety in...

WCLC 2024: Results from CARMEN-LC03 phase 3 study of tusamitamab ravtansine vs. docetaxel in previously treated advanced non-squamous NSCLC

WCLC 2024: Results from CARMEN-LC03 phase 3 study of tusamitamab ravtansine vs. docetaxel in previously treated...

PM2.5 exposure may affect lung cancer in women who have never smoked

PM2.5 exposure may affect lung cancer in women who have never smoked

WCLC 2024: LUMINOSITY trial demonstrates telisotuzumab vedotin shows durable response in Asian patients with c-Met protein-overexpressing EGFR WT nonsquamous NSCLC

WCLC 2024: LUMINOSITY trial demonstrates telisotuzumab vedotin shows durable response in Asian patients with c-Met...

WCLC 2024: Aumolertinib maintenance after chemoradiotherapy in stage III non-small cell lung cancer improves PFS compared to placebo

WCLC 2024: Aumolertinib maintenance after chemoradiotherapy in stage III non-small cell lung cancer improves PFS...

WCLC 2024: Osimertinib with savolitinib demonstrates stronger efficacy than osimertinib alone in patients who do not respond well to EGFR-TKIs therapy

WCLC 2024: Osimertinib with savolitinib demonstrates stronger efficacy than osimertinib alone in patients who do...

More from ecancer